Trials / Completed
CompletedNCT00354653
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Iran is uncertain. This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAMIVUDINE |
Timeline
- Start date
- 2002-02-09
- Primary completion
- 2007-01-23
- Completion
- 2007-01-23
- First posted
- 2006-07-20
- Last updated
- 2020-03-03
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT00354653. Inclusion in this directory is not an endorsement.